FindTrial
Sign In

chemotherapy drugs

DRUG4 trials

Sponsors

ARCAGY/ GINECO GROUP, Shenzhen Fifth People's Hospital, Xi'an Jiaotong University, Tianjin Medical University Cancer Institute and Hospital

Conditions

Acute LeukemiaCancer, Therapy-RelatedEndometrial CarcinosarcomaImmune-related Adverse EventMalignant Solid TumorsOvarian CarcinosarcomaPancreatic Cancer ResectableSerum Ferritin

Phase 2

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
RecruitingNCT03651206
ARCAGY/ GINECO GROUPEndometrial Carcinosarcoma, Ovarian Carcinosarcoma
Start: 2020-07-15End: 2027-06-30Target: 138Updated: 2025-12-19

Phase 4

The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol
NCT03777930
Shenzhen Fifth People's HospitalCancer, Therapy-Related
Start: 2018-12-10End: 2021-06-10Target: 200Updated: 2018-12-19
The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
RecruitingNCT06368063
Xi'an Jiaotong UniversityPancreatic Cancer Resectable
Start: 2024-05-06End: 2028-03-31Target: 642Updated: 2024-05-08

Unknown Phase

The Effect of Serum Ferritin in irAE
RecruitingNCT06702566
Tianjin Medical University Cancer Institute and HospitalAcute Leukemia, Immune-related Adverse Event, Malignant Solid Tumors +1
Start: 2024-07-04End: 2027-07-01Target: 1500Updated: 2024-11-25

Related Papers

Abstract 5273: Changes in the tumor immune microenvironment during disease progression in gynecological carcinosarcoma: Exploratory analysis from the randomized ROCSAN GINECO trial
Cancer Research2025-04-21
34O ROCSAN: A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum-based chemotherapy – Preliminary results
ESMO Open2024-06-012 citations
Dostarlimab: A Review.
2022-07-2639 citations